NOVN Stock Chart & Stats
$0.07
-$0.02(-22.22%)
―
--
Day’s Range― - ―
52-Week Range$0.03 - $3.33
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$28.00
Enterprise Value$25.50
Total Cash (Recent Filing)$12.54M
Total Debt (Recent Filing)$3.85M
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Novan News
NOVN FAQ
What was Novan Inc’s price range in the past 12 months?
Novan Inc lowest stock price was $0.03 and its highest was $3.33 in the past 12 months.
What is Novan Inc’s market cap?
Novan Inc’s market cap is $28.00.
When is Novan Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Novan Inc’s earnings last quarter?
Currently, no data Available
Is Novan Inc overvalued?
According to Wall Street analysts Novan Inc’s price is currently Undervalued.
Does Novan Inc pay dividends?
Novan Inc does not currently pay dividends.
What is Novan Inc’s EPS estimate?
Novan Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novan Inc have?
Currently, no data Available
What happened to Novan Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Novan Inc?
Currently, no hedge funds are holding shares in NOVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novan Inc
Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in nitric oxide-derived therapies for dermatological and anti-infective conditions. The company boasts a robust clinical-stage pipeline featuring several topical drug candidates. For skin-related ailments, these include SB204, a monotherapy aimed at acne vulgaris; SB206, an antiviral gel targeting viral skin infections; SB208, a broad-spectrum antifungal gel designed to combat various fungal skin and nail infections like athlete's foot; and SB414, a cream-based gel formulated for inflammatory skin diseases. Additionally, Novan is advancing SB207 to treat external genital warts, WH602 (an intravaginal gel) and WH504 (a non-gel formulation) both addressing high-risk human papillomavirus (HPV), and SB019, a candidate for SARS-CoV-2. The firm has cultivated strategic partnerships, holding a licensing agreement with Sato Pharmaceutical Co., Ltd., and engaging in a strategic alliance with Orion Corporation. Founded in 2006, Novan, Inc. maintains its headquarters in Durham, North Carolina.
EyePoint Pharmaceuticals
―
TuHURA Biosciences
―
Oragenics
―
Insmed
―
―
Cumberland Pharmaceuticals
―